2023-09-12 インペリアル・カレッジ・ロンドン(ICL)
◆研究者は、治療開始後の最初の1年間が特に重要であり、この期間に患者の服薬状況を確認し、サポートが必要かどうかを検討すべきであると指摘しています。
<関連情報>
- https://www.imperial.ac.uk/news/247594/health-young-people-with-ulcerative-colitis/
- https://bjgp.org/content/early/2023/09/01/BJGP.2023.0006
潰瘍性大腸炎の若年者における5-アミノサリチル酸維持療法のアドヒアランス:プライマリ・ケアにおけるレトロスペクティブ・コホート研究 Adherence to 5-aminosalicylic acid maintenance treatment in young people with ulcerative colitis: a retrospective cohort study in primary care
Nishani Jayasooriya, Richard C Pollok, Jonathan Blackwell, Alex Bottle, Irene Petersen, Hanna Creese and Sonia Saxena The POP-IBD study group
British Journal of General Practice Published:4 September 2023
DOI: https://doi.org/10.3399/BJGP.2023.0006
Abstract
Background Maintenance treatment with 5-aminosalicylic acid (5-ASA) is recommended in ulcerative colitis (UC), but accurate estimates of discontinuation and adherence in adolescents transitioning to young adulthood are lacking.
Aim To determine rates and risk factors for discontinuation and adherence to oral 5-ASA in adolescents and young adults 1 year following diagnosis of UC.
Design and setting Observational cohort study using the UK Clinical Practice Research Datalink among adolescents and young adults (aged 10–24 years) diagnosed with UC between 1 January 1998 and 1 May 2016.
Method Time to oral 5-ASA discontinuation (days) and adherence rates (proportion of days covered) were calculated during the first year of treatment using Kaplan–Meier survival analysis. Cox regression models were built to estimate the impact of sociodemographic and health-related risk factors.
Results Among 607 adolescents and young adults starting oral 5-ASA maintenance treatment, one-quarter (n = 152) discontinued within 1 month and two- thirds (n = 419) within 1 year. Discontinuation was higher among those aged 18–24 years (74%) than younger age groups (61% and 56% in those aged 10–14 and 15–17 years, respectively). Adherence was lower among young adults than adolescents (69% in those aged 18–24 years versus 80% in those aged 10–14 years). Residents in deprived versus affluent postcodes were more likely to discontinue treatment (adjusted hazard ratio [aHR] 1.46, 95% confidence interval [CI] = 1.10 to 1.92). Early corticosteroid use for an acute flare lowered the likelihood of oral 5-ASA discontinuation (aHR 0.68, 95% CI = 0.51 to 0.90).
Conclusion The first year of starting long-term therapies in adolescents and young adults diagnosed with UC is a critical window for active follow-up of maintenance treatment, particularly in those aged 18–24 years and those living in deprived postcodes.
